Glaxo get Indian market rights for Japanese medicine

May 5th, 2008 - 3:23 pm ICT by admin  

Mumbai May 5 (IANS) Pharma major GlaxoSmithKline (GSK) has bagged a deal to sell Japan based Astellas Pharma Inc’s popular injectible anti-fungal agent Micafungin in India. Announcing this Monday, GlaxoSmithKline said the deal gives it exclusive market rights for the sale of Micafungin (brand name Mycamine) in India.

Micafungin, belonging to a new class of anti-fungal agents used in the medication of deep seated Candida infections, was initially approved by Japanese Agency in 2002, by the US in 2005 followed by other countries.

Tags: , , , , , , , , , , , , , , ,

Posted in Business |